Abstract
We conducted a retrospective study of stereotactic ablative radiotherapy (SABR) for 94 patients with non-small-cell lung cancer at our institution. The patients were treated with either 50 Gy in five treatments or 48 Gy in four treatments, corresponding to biologically effective doses (BED) of 100 Gy or 105.6 Gy, respectively. The results demonstrate that, with relatively low BEDs, we can achieve excellent local control with minimal toxicity.
Keywords:
Biologically effective dose; Lung cancer; Non-small-cell lung cancer; Radiation oncology; Radiotherapy.
MeSH terms
-
Adenocarcinoma / pathology
-
Adenocarcinoma / surgery
-
Aged
-
Aged, 80 and over
-
Carcinoma, Non-Small-Cell Lung / pathology
-
Carcinoma, Non-Small-Cell Lung / surgery*
-
Carcinoma, Squamous Cell / pathology
-
Carcinoma, Squamous Cell / surgery
-
Dose Fractionation, Radiation*
-
Female
-
Follow-Up Studies
-
Humans
-
Lung Neoplasms / pathology
-
Lung Neoplasms / surgery*
-
Male
-
Middle Aged
-
Neoplasm Recurrence, Local / prevention & control*
-
Prognosis
-
Radiation Pneumonitis / prevention & control*
-
Radiosurgery / methods*
-
Radiotherapy Planning, Computer-Assisted
-
Retrospective Studies
-
Survival Rate